Compositions and methods for treating diabetes
AssigneeWaratah Pharmaceuticals, Inc.
InventorsStephen J. Brand, Antonio Cruz
Life of this patent
Estimating the term…
Abstract
Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.
Claims6
-77. (canceled)
A pharmaceutical composition comprising an agent for suppressing an immune response and a gastrin/CCK receptor ligand in the absence of a EGF receptor ligand, wherein the agent for suppressing immune response is at least one selected from the group consisting of:
- hul 124;
- BTI-322;
- allotrap-HLA-B270;
- OKT4A;
- Enlimomab;
- ABX-CBL;
- OKT3;
- ATGAM;
- basiliximab;
- daclizumab;
- antithymocyte immunoglobulin;
- ISAtx247;
- Medi-500;
- Medi-507;
- Alefacept;
- efalizumab;
- infliximab;
- and an interferon and the gastrin/CCK receptor ligand is gastrin 17(Leu 15).
A method of treating a diabetic subject comprising administering to said subject an agent that increases islet neogenesis and an agent that suppresses an immune response in the absence of a EGF receptor ligand, wherein said agent that increases islet neogenesis is gastrin 17(Leu 15) and wherein the agent for suppressing immune response is at least one selected from the group consisting of:
- hul 124;
- BTI-322;
- allotrap-HLA-B270;
- OKT4A;
- Enlimomab;
- ABX-CBL;
- OKT3;
- ATGAM;
- basiliximab;
- daclizumab;
- antithymocyte immunoglobulin;
- ISAtx247;
- Medi-500;
- Medi-507;
- Alefacept;
- efalizumab;
- infliximab;
- and an interferon and the gastrin/CCK receptor ligand is gastrin 17(Leu 15).
Dependencies are inferred from the claim text.